Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...